A Dark Vector Cognition product

Cardinal Health 10-Q 2023-03-31

CAH · CIK 721371 · Form 10-Q · Period ended March 31, 2023 · Filed May 4, 2023

Revenue rose 12.6% to $50.5 billion. Operating margin was 1.1%, against -0.2% a year earlier. Net income was $345 million.

7 sections, 220K characters. Original on sec.gov · ·

Risk FactorsBusiness

Key numbers
MeasureQuarter ended Mar 31, 2023Quarter ended Mar 31, 2022Change
Revenue$50.5B$44.8B+12.6%
Operating income$572M-$97.0Mn/a
Net income$345M-$1.39Bn/a
Cash and equivalents$3.99Bn/an/a
Operating margin*1.1%-0.2%+1.3 pts

From the XBRL facts tagged to this filing; both columns are as reported in this filing. * Computed by filings.tools: free cash flow is operating cash flow less capital spending; operating margin is operating income over revenue.

The 112 tables in this filing as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Cover and table of contents

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2023

or

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

Commission File Number: 1-11373

Cardinal Health, Inc.

(Exact name of registrant as specified in its charter)

Ohio31-0958666
(State or other jurisdiction of incorporation or organization)(IRS Employer Identification No.)
7000 Cardinal Place,Dublin,Ohio43017
(Address of principal executive offices)(Zip Code)

(614) 757-5000

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common shares (without par value)CAHNew York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer☑Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No þ

The number of the registrant’s common shares, without par value, outstanding as of April 30, 2023, was the following: 254,600,182.

Cardinal Health Q3 Fiscal 2023 Form 10-Q

Table of Contents

Page
Management's Discussion and Analysis of Financial Condition and Results of Operations2
Explanation and Reconciliation of Non-GAAP Financial Measures16
Quantitative and Qualitative Disclosures about Market Risk21
Controls and Procedures21
Legal Proceedings22
Risk Factors23
Unregistered Sales of Equity Securities and Use of Proceeds25
Financial Statements26
Exhibits44
Form 10-Q Cross Reference Index45
Signatures46

About Cardinal Health

Cardinal Health, Inc., an Ohio corporation formed in 1979, is a globally integrated healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency. We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. We manage our business and report our financial results in two segments: Pharmaceutical and Medical. As used in this report, “we,” “our,” “us,” and similar pronouns refer to Cardinal Health, Inc. and its majority-owned and consolidated subsidiaries, unless the context requires otherwise. Our fiscal year ends on June 30. References to fiscal 2023 and fiscal 2022 and to FY23 and FY22 are to the fiscal years ending or ended June 30, 2023 and June 30, 2022, respectively.

Forward-Looking Statements

This Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (this "Form 10-Q") (including information incorporated by reference) includes "forward-looking statements" addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. Many forward-looking statements appear in Management’s Discussion and Analysis of Financial Condition and Results of Operations ("MD&A"), but there are others in this Form 10-Q, which may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those made, projected or implied. The most significant of these risks and uncertainties are described in this Form 10-Q, including Exhibit 99.1, and in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (our “2022 Form 10-K”). Forward-looking statements in this Form 10-Q speak only as of the date of this document. Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.

Non-GAAP Financial Measures

In the "Overview of Consolidated Results" section of MD&A, we use financial measures that are derived from our consolidated financial data but are not presented in our condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These measures are considered "non-GAAP financial measures" under the United States Securities and Exchange Commission ("SEC") rules. The reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures are included in the “Explanation and Reconciliation of Non-GAAP Financial Measures” section following MD&A in this Form 10-Q.

1Cardinal Health | Q3 Fiscal 2023 Form 10-Q

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

MD&AOverview

Management's Discussion and Analysis of Financial Condition and Results of Operations

The discussion and analysis presented below is concerned with material changes in financial condition and results of operations, including amounts and certainty of cash flows from operations and from outside sources, between the periods specified in our condensed consolidated balance sheets at March 31, 2023 and June 30, 2022, and in our condensed consolidated statements of earnings/(loss) for the three and nine months ended March 31, 2023 and 2022. All comparisons presented are with respect to the prior-year period, unless stated otherwise. This discussion and analysis should be read in conjunction with the MD&A included in our 2022 Form 10-K.

2Cardinal Health | Q3 Fiscal 2023 Form 10-Q
MD&AOverview

Overview of Consolidated Results

Revenue

During the three and nine months ended March 31, 2023, revenue increased 13 percent to $50.5 billion and $151.6 billion, respectively, primarily due to branded and specialty pharmaceutical sales growth from existing customers. During the nine months ended March 31, 2023, pharmaceutical sales growth from net new customers also contributed to increased revenue.

GAAP and Non-GAAP Operating Earnings/(Loss)

Three Months Ended March 31,Nine Months Ended March 31,
(in millions)20232022Change20232022Change
GAAP operating earnings/(loss)$572$(97)N.M.$590$(632)N.M.
Surgical gown recall costs/(income)———1
State opioid assessment related to prior fiscal years——(6)—
Shareholder cooperation agreement costs——8—
Restructuring and employee severance16316256
Amortization and other acquisition-related costs7479216237
Impairments and (gain)/loss on disposal of assets, net204718831,764
Litigation (recoveries)/charges, net(76)61(256)113
Non-GAAP operating earnings$606$54511%$1,497$1,540(3)%

The sum of the components and certain computations may reflect rounding adjustments.

We had GAAP operating earnings of $572 million during the three months ended March 31, 2023 and a GAAP operating loss of $97 million during the three months ended March 31, 2022, which reflects no goodwill impairment charge recognized during the three months ended March 31, 2023 and the $474 million pre-tax non-cash goodwill impairment charge related to the Medical segment recognized during the three months ended March 31, 2022.

We had GAAP operating earnings of $590 million and a GAAP operating loss of $632 million during the nine months ended March 31, 2023 and 2022, respectively, which included the $863 million and $1.8 billion pre-tax non-cash goodwill impairment charges related to the Medical segment, respectively. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&A and Note 4 of the "Notes to Condensed Consolidated Financial Statements" for additional detail related to goodwill impairment.

GAAP operating earnings during the three and nine months ended March 31, 2023 were favorably impacted by litigation recoveries. See "Results of Operations" section of this MD&A and Note 6 of the "Notes to Condensed Consolidated Financial Statements" for additional detail related to litigation recoveries.

Non-GAAP operating earnings during the three months ended March 31, 2023 increased 11 percent to $606 million primarily due to an increase in Pharmaceutical segment profit largely driven by the performance of our generics program and an increased contribution from branded and specialty pharmaceutical products. This increase was partially offset by a decrease in Medical segment profit largely resulting from lower volumes and unfavorable product sales mix within products and distribution.

Non-GAAP operating earnings during the nine months ended March 31, 2023 decreased 3 percent to $1.5 billion primarily due to a decrease in Medical segment profit largely resulting from lower volumes and unfavorable product sales mix within products and distribution and net inflationary impacts. This decrease was partially offset by an increase in Pharmaceutical segment profit primarily driven by the performance of our generics program and an increased contribution from branded and specialty pharmaceutical products.

3Cardinal Health | Q3 Fiscal 2023 Form 10-Q
MD&AOverview

GAAP and Non-GAAP Diluted EPS

Three Months Ended March 31,Nine Months Ended March 31,
($ per share)20232022(2)Change20232022(2)Change
GAAP diluted EPS (1)$1.34$(5.05)N.M.$1.23$(3.82)N.M.

Showing the first 8K of 83K characters. Open the full section

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes in the quantitative and qualitative market risk disclosures included in our 2022 Form 10-K since the end of fiscal 2022 through March 31, 2023.

Item 4. Controls and Procedures

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) as of March 31, 2023. Based on this evaluation, our principal executive officer and principal financial officer have concluded that as of March 31, 2023, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

21Cardinal Health | Q3 Fiscal 2023 Form 10-Q
Other

Legal Proceedings

In addition to the proceeding described below, the legal proceedings described in Note 6 of the "Notes to Condensed Consolidated Financial Statements" are incorporated in this "Legal Proceedings" section by reference.

Between June 2019 and January 2020, three purported shareholders filed actions on behalf of Cardinal Health, Inc. in the U.S. District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation. In January, 2020, the court consolidated these derivative cases under the caption In re Cardinal Health, Inc. Derivative Litigation and in March 2020, plaintiffs filed an amended complaint.

In December 2021, the parties reached an agreement in principle to settle this matter and in October 2022, the court entered an order approving the settlement and dismissing the case. This settlement does not include any admission of liability. Under the settlement, in December 2022, Cardinal Health's director and officer liability insurance carriers, on behalf of the defendants, paid Cardinal Health $124 million, less approximately $31 million in attorneys' fees and expenses awarded by the court to plaintiffs' counsel.

22Cardinal Health | Q3 Fiscal 2023 Form 10-Q

Item 1A. Risk Factors

Other

Risk Factors

You should carefully consider the information in this Form 10-Q, including the Risk Factors below, and the risk factors discussed in "Risk Factors" and other risks discussed in our 2022 Form 10-K, our Form 10-Q for the quarter ended December 31, 2022 and September 30, 2022, and our other filings with the SEC since June 30, 2022. These risks could materially and adversely affect our results of operations, financial condition, liquidity, and cash flows. Our business also could be affected by risks that we are not presently aware of or that we currently consider immaterial to our operations.

Our business could be affected by activist shareholders.

In September 2022, we entered into a Cooperation Agreement (the "Cooperation Agreement") with Elliott Associates, L.P. and Elliott International, L.P. (together, "Elliott") under which our Board of Directors, among other things, (1) appointed four new independent directors, including a representative from Elliott , and (2) formed an advisory Business Review Committee of the Board, which is tasked with undertaking a comprehensive review of our strategy, portfolio, capital-allocation framework and operations. In May 2023, we extended the term of the Cooperation Agreement until the later of July 15, 2024 or until Elliott's representative ceases to serve on, or resigns from, our Board of Directors.

The Cooperation Agreement may create unintended consequences, such as creating uncertainty about our management, operations or future strategic direction, which could result in the loss of future business opportunities or negatively impact our ability to attract and retain qualified talent. Additionally, implementing any actions recommended by the Business Review Committee and the Board may be costly and time-consuming, may be disruptive to our ongoing business operations and may ultimately be unsuccessful.

It is possible that activist shareholders may, among other things, attempt to effect additional changes and exert influence over our Board of Directors and management or initiate a proxy contest, which may disrupt our operations by diverting the attention of management and the Board and be costly and time-consuming. Any such proxy contests, actions or requests, or the mere public presence of activist shareholders, may cause the market price for our shares to experience volatility, which could be significant.

We could be subject to adverse changes in the tax laws or additional challenges to our tax positions.

We are a large multinational corporation with operations in the United States and many foreign countries. As a result, we are subject to the tax laws of many jurisdictions.

From time to time, proposals are made in the United States and other jurisdictions in which we operate that could adversely affect our tax positions, effective tax rate or tax payments. Specific initiatives that may impact us include possible increases in U.S. or foreign corporate income tax rates or other changes in tax law to raise revenue, the repeal of the LIFO (last-in, first-out) method of inventory accounting for income tax purposes, the establishment or increase in taxation at the U.S. state level on the basis of gross revenues, recommendations of the base erosion and profit shifting project undertaken by the Organization for Economic Cooperation and Development and the European Commission’s investigation

into illegal state aid. In August 2022, the U.S. federal government enacted the Inflation Reduction Act, which imposed a 15 percent corporate minimum tax on certain large corporations and a 1 percent tax on share repurchases after December 31, 2022. These provisions may adversely impact our financial position and results of operations.

Additionally, in connection with the accruals taken in connection with opioid-related lawsuits in fiscal years 2021 and 2020, we recorded net tax benefits of $228 million and $488 million, respectively, reflecting our current assessment of the estimated future deductibility of the amount that may be paid. We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment, and it is possible that they could be subject to challenges by the U.S. Internal Revenue Service ("IRS").

The U.S. tax law governing deductibility was changed by the Tax Act. The taxing authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits, or tax law could change again. We also regularly review these estimates and assumptions from time to time and adjust our accruals based on our review, resulting in changes in our tax provision/(benefit). The actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates. See Note 7 of the "Notes to Condensed Consolidated Financial Statements" for more information regarding these matters.

In fiscal year 2021, our provision for income taxes reflected a $424 million benefit from the tax benefits of a self-insurance pre-tax net operating loss carryback under the Coronavirus Aid, Relief and Economic Security (“CARES”) Act. Also, as a result of this net operating loss carryback, we received a U.S. federal income tax refund of $966 million. In connection with this net operating loss carryback, certain industry participants, including us, received a letter from the U.S. House of Representatives’ Committee on Oversight and Reform questioning, among other things, our plans to take tax deductions for opioid-related losses, including our use of the net operating loss carryback provisions under the CARES Act and deductibility under the Tax Act. We responded to the letter. It is possible that the IRS could challenge our tax position with respect to this self-insurance loss. If these initiatives are successful, our effective tax rate could be adversely impacted. Additionally, laws governing insurance coverage vary by state and

23Cardinal Health | Q3 Fiscal 2023 Form 10-Q
Other

some state courts have interpreted laws and insurance policies in ways that may impact our self-insurance loss, which could negatively impact our financial position.

We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. Tax laws are complex and subject to varying interpretations. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year. Proposed adjustments in ongoing audits may adversely affect our effective tax rate or tax payments.

24Cardinal Health | Q3 Fiscal 2023 Form 10-Q
Other

Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

PeriodTotal Number of Shares Purchased (1)Average Price Paid per Share (2,3)Total Number of Shares Purchased as Part of Publicly Announced Programs (2,3,4)Approximate Dollar Value of Shares That May Yet be Purchased Under the Program (4) (in millions)
January 2023614,596$81.40614,248$1,493
February 20232,596,57077.032,596,3911,293
March 2023639,11578.25638,9301,243
Total3,850,281$77.933,849,569$1,243

(1)Reflects 348, 179 and 185 common shares purchased in January, February, and March 2023, respectively, through a rabbi trust as investments of participants in our Deferred Compensation Plan.

(2)On February 6, 2023, we entered into an accelerated share repurchase ("ASR") program to purchase common shares for an aggregate purchase price of $250 million and received an initial delivery of 2.6 million common shares using a reference price of $77.03. The ASR program concluded on February 28, 2023 at a volume weighted average price per common share of $77.27 resulting in a final delivery of 0.6 million common shares. See Note 10 of the "Notes to Condensed Consolidated Financial Statements" for additional information.

(3)On November 17, 2022, we entered into an ASR program to purchase common shares for an aggregate purchase price of $250 million and received an initial delivery of 2.6 million common shares using a reference price of $76.58. The ASR program concluded on January 13, 2023 at a volume weighted average price per common share of $77.50 resulting in a final delivery of 0.6 million common shares. See Note 10 of the "Notes to Condensed Consolidated Financial Statements" for additional information.

(4)On November 4, 2021, our Board of Directors approved a new $3.0 billion share repurchase program, which will expire on December 31, 2024. As of March 31, 2023, we have $1.2 billion authorized for share repurchases remaining under this program.

25Cardinal Health | Q3 Fiscal 2023 Form 10-Q
Financial Statements

Item 1. Financial Statements

Condensed Consolidated Statements of Earnings/(Loss)

(Unaudited)

Three Months Ended March 31,Nine Months Ended March 31,
(in millions, except per common share amounts)2023202220232022
Revenue$50,487$44,836$151,559$134,261
Cost of products sold48,70243,154146,497129,321
Gross margin1,7851,6825,0624,940
Operating expenses:
Distribution, selling, general and administrative expenses1,1791,1373,5673,402
Restructuring and employee severance16316256
Amortization and other acquisition-related costs7479216237
Impairments and (gain)/loss on disposal of assets, net204718831,764
Litigation (recoveries)/charges, net(76)61(256)113
Operating earnings/(loss)572(97)590(632)
Other (income)/expense, net—3(5)(14)
Interest expense, net283878115
Loss on early extinguishment of debt———10
(Gain)/loss on sale of equity interest in naviHealth—(1)—(2)
Earnings/(loss) before income taxes544(137)517(741)
Provision for income taxes1971,253189328
Net earnings/(loss)347(1,390)328(1,069)
Less: Net earnings attributable to noncontrolling interests(2)(1)(3)(2)
Net earnings/(loss) attributable to Cardinal Health, Inc.$345$(1,391)$325$(1,071)
Earnings/(Loss) per common share attributable to Cardinal Health, Inc.:
Basic$1.35$(5.05)$1.24$(3.82)
Diluted1.34(5.05)1.23(3.82)
Weighted-average number of common shares outstanding:
Basic256275263281
Diluted258275264281
Cash dividends declared per common share$0.4957$0.4908$1.4871$1.4724

See notes to condensed consolidated financial statements.

26Cardinal Health | Q3 Fiscal 2023 Form 10-Q
Financial Statements

Condensed Consolidated Statements of Comprehensive Income/(Loss)

(Unaudited)

Three Months Ended March 31,Nine Months Ended March 31,
(in millions)2023202220232022
Net earnings/(loss)$347$(1,390)$328$(1,069)
Other comprehensive income/(loss):
Foreign currency translation adjustments and other4(4)(34)(47)
Net unrealized gain on derivative instruments, net of tax—1264
Total other comprehensive income/(loss), net of tax48(28)(43)
Total comprehensive income/(loss)351(1,382)300(1,112)
Less: comprehensive income attributable to noncontrolling interests(2)(1)(3)(2)
Total comprehensive income/(loss) attributable to Cardinal Health, Inc.$349$(1,383)$297$(1,114)

See notes to condensed consolidated financial statements.

27Cardinal Health | Q3 Fiscal 2023 Form 10-Q
Financial Statements

Condensed Consolidated Balance Sheets

(in millions)March 31, 2023June 30, 2022
(Unaudited)
Assets
Current assets:
Cash and equivalents

Showing the first 8K of 106K characters. Open the full section

Item 6. Exhibits

Exhibits

Exhibits

Exhibit NumberExhibit Description
3.1Amended and Restated Articles of Incorporation of Cardinal Health, Inc., as amended (incorporated by reference to Exhibit 3.1 to Cardinal Health’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, File No. 1-11373)
3.2Cardinal Health, Inc. Restated Code of Regulations, as amended (incorporated by reference to Exhibit 3.2 to Cardinal Health’s Quarterly Report on Form 10-Q filed on November 9, 2021, File No. 1-11373)
10.1Third Amended and Restated Five-Year Credit Agreement, dated as of February 27, 2023 (incorporated by reference to Exhibit 10.1 to Cardinal Health's Current Report on Form 8-K filed on March 2, 2023, File No. 1-11373)
31.1Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
99.1Statement Regarding Forward-Looking Information
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEFInline XBRL Taxonomy Definition Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File - formatted in Inline XBRL (included as Exhibit 101)

Cardinal Health Website

Cardinal Health uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive e-mail alerts when we post news releases, SEC filings and certain other information on its website.

44Cardinal Health | Q3 Fiscal 2023 Form 10-Q
Form 10-Q Cross Reference Index

Form 10-Q Cross Reference Index

Item NumberPage
Part I. Financial Information
Item 1Financial Statements26
Item 2Management's Discussion and Analysis of Financial Condition and Results of Operations2
Item 3Quantitative and Qualitative Disclosures about Market Risk21
Item 4Controls and Procedures21
Part II. Other Information
Item 1Legal Proceedings22
Item 1ARisk Factors23
Item 2Unregistered Sales of Equity Securities and Use of Proceeds25
Item 3Defaults Upon Senior SecuritiesN/A
Item 4Mine Safety DisclosuresN/A
Item 5Other InformationN/A
Item 6Exhibits44
Signatures46
N/ANot applicable
45Cardinal Health | Q3 Fiscal 2023 Form 10-Q
Additional Information

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Cardinal Health, Inc.
Date:May 4, 2023/s/ JASON M. HOLLAR
Jason M. Hollar
Chief Executive Officer
/s/ AARON E. ALT
Aaron E. Alt
Chief Financial Officer
46Cardinal Health | Q3 Fiscal 2023 Form 10-Q